TrialBMJ open2017

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).

Eleonora Dalla Bella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.